Background. The effects of β-blockers in patients with unstable angina pectoris (UAP) are unclear. We tried to evaluate associations between β-blockers in UAP and long-term outcomes. Methods. We enrolled 5591 UAP patients and divided them into 2 groups based on β-blockers at discharge: 3790 did β-blockers and 1801 did not used them. Propensity score matching at 1 : 1 was performed to select 1786 patients from each group. The primary endpoint was major adverse cardiac and cerebral events (MACCE) during the long-term follow-up period. Results. 67.8% of patients were on β-blockers at discharge; these patients were more likely to have CHD risk factors, lower ejection fraction, and severity of the coronary artery lesions. Over a median of 25.0 years, the incidence of MACCE was 25.5%. The risk was not significantly different between those on and those not on β-blocker treatment. The multivariate Cox regression analysis showed that no β-blocker use at discharge was not an independent risk factor for MACCE and sequence secondary endpoints. After propensity score matching, the results were similar. Conclusions. β-blocker use was not associated with lower MACCE and other secondary composite endpoints in long-term outcomes. This result adds to the increasing body of evidence that the routine prescription of β-blockers might not be indicated in patients with UAP. Trial registration had retrospectively registered.

中文翻译：

---

不稳定型心绞痛患者出院时 β 受体阻滞剂治疗与长期随访结果的相关性

背景。β受体阻滞剂对不稳定型心绞痛（UAP）患者的作用尚不清楚。我们试图评估UAP 中的β受体阻滞剂与长期结果之间的关联。方法。我们招募了 5591 名 UAP 患者，并根据出院时的β受体阻滞剂将他们分为 2 组：3790 人使用β受体阻滞剂，1801 人未使用。进行了 1:1 的倾向评分匹配，以从每组中选择 1786 名患者。主要终点是长期随访期间的主要不良心脑事件（MACCE）。结果。67.8% 的患者使用β- 出院时的阻滞剂；这些患者更可能有冠心病危险因素、射血分数较低和冠状动脉病变的严重程度。超过 25.0 年的中位数，MACCE 的发生率为 25.5%。接受和未接受β受体阻滞剂治疗的患者的风险没有显着差异。多变量 Cox 回归分析表明，出院时未使用β受体阻滞剂并不是 MACCE 和序列次要终点的独立危险因素。倾向得分匹配后，结果相似。结论。β受体阻滞剂的使用与长期结局中较低的 MACCE 和其他次要复合终点无关。这一结果增加了越来越多的证据表明常规处方β受体阻滞剂可能不适用于 UAP 患者。试验登记已追溯登记。